Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-08-23
2011-08-23
Chu, Yong (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S415000, C546S201000, C548S469000, C548S511000
Reexamination Certificate
active
08003670
ABSTRACT:
The present invention relates to novel aminoalkoxy arylsulfonamide compounds of the formula (I), their derivatives, their stereoisomers, their pharmaceutically acceptable salts and pharmaceutically acceptable compositions containing them. The present invention also relates to a process for the preparation of above said novel compounds, their derivatives, their stereoisomers, their pharmaceutically acceptable salts and pharmaceutically acceptable compositions containing them. These compounds are useful in the treatment of various disorders that are related to 5-HT6receptor functions. Specifically, the compounds of this invention are also useful in the treatment of various CNS disorders, hematological disorders, eating disorders, diseases associated with pain, respiratory diseases, genito-urological disorders, cardiovascular diseases and cancer.
REFERENCES:
patent: WO 98/27081 (1998-06-01), None
patent: WO 99/02502 (1999-01-01), None
patent: WO 99/37623 (1999-07-01), None
patent: WO 99/42465 (1999-08-01), None
patent: WO 00/63203 (2000-10-01), None
patent: WO 01/32646 (2001-05-01), None
patent: WO 02/36562 (2002-05-01), None
patent: WO 02/060871 (2002-08-01), None
patent: WO 02/098857 (2002-12-01), None
patent: WO 02/098878 (2002-12-01), None
patent: WO 03/013510 (2003-02-01), None
patent: WO 03/065046 (2003-08-01), None
patent: WO 03/066056 (2003-08-01), None
patent: WO 03/080580 (2003-10-01), None
patent: WO 2004/048328 (2004-06-01), None
patent: WO 2004/048330 (2004-06-01), None
patent: WO 2004/048331 (2004-06-01), None
patent: WO 2004/055026 (2004-07-01), None
patent: WO 2004056361 (2004-07-01), None
patent: WO 2005/013974 (2005-02-01), None
patent: WO 2006038594 (2006-04-01), None
patent: WO 2007/020652 (2007-02-01), None
Vippagunta et al., Advanced Drug Delivery Reviews, vol. 48, p. 3-26 ( on p. 3), 2001.
Monsma et al., Molec. Pharmacol. 43:320-327 (1993).
Kohen et al., J. Neurochem. 66:47-56 (1996).
Ruat et al., Biochem. Biophys. Res. Comm. 193:268-276 (1993).
Ward et al., Neurosci. 64:1105-1111 (1995).
Reavill and Rogers, Curr. Opin. Invest. Drugs 2(1):104-109 (2001).
Stean et al., Br. J. Pharmacol. 127 Proc. Supplement 131P (1999).
Routledge et al., Br. J. Pharmacol. 130:1606-1612 (2000).
Gerard et al., Brain Research 746:207-219 (1997).
Bentley et al., Br. J. Pharmacol. 126(7):1537-1542 (1999).
Dawson et al., Br. J. Pharmacol. 130(1):23-26 (2000).
Rogers et al., Society of Neuroscience, Abstracts 26:680 (2000).
Ernst et al., J. Neuroscience 18(15):5901-5907 (1998).
Cole et al., WAY-181187 230th ACS National Meet. (Aug. 28-Sep. 1, 2005 Wash.D.C.) Abstract MEDI 17.
Branchek and Blackburn, Ann. Rev. Pharm. Toxicol. 40:319-334 (2000).
Roth et al., J. Pharmacol. Exper. Therapeut. 268:1403-12 (1994).
Fox et al., J. Neurochem. 65(6):2796-99 (1995).
Wooley et al., Neuropharmacol. 41:210-29 (2001).
Holenz et al., Drug Discovery Today 11(7/8):283-299 (Apr. 2006).
Glennon et al., J. Med. Chem. 43:1011-1018 (2000).
Tsai et al., Bioorg. Med. Chem. Lett. 10:2295-99 (2000).
Demchyshyn et al., 31st Ann. Meet. Soc. Neurosci. Nov. 10-15, Abstr. 266.6 (2001).
Mattson et al., Bioorg. Med. Chem. Lett. 15:4230-34 (2005).
Pullagurla MR, Westkaemper RB, Glennon RA, “Possible differences in modes of agonist and antagonist binding at human 5-HT6 receptors.” Bioorg. Med. Chem. Lett. 14:4569-4573 (2004).
Bromidge et al., J. Med. Chem. 42:202-205 (1999).
Bromidge et al., Bioorg. Med. Chem. Lett. 11:55-58 (2001).
Hirst et al., 33rd Ann. Meet. Soc. Neurosci. (Nov. 8-12 New Orleans) Abstr. 576.7 (2003).
Bonhaus et al., 32nd Ann. Meet. Soc. Neurosci. Abstr. 884.5 (2002).
Sleight et al., Br. J. Pharmacol. 124:556-62 (1998).
Pouzet et al., Pharmacol. Biochem. Behav. 71:635-643 (2002).
Berge et al., J. Pharm. Sci. 66:1-19 (1977).
Kask et al., Eur. J. PHarmacol. 414:215-224 (2001).
Turnbull et al., Diabetes 51:2441-2449 (2002).
Ennaceur, Behav. Brain Res. 31:47-59 (1988).
King et al., Neuropharmacol. 47:195-204 (2004).
Yamada et al., Pharmacol. Biochem. and Behaviour 78:787-91 (2004).
Lindner et al., J. Pharmacol. Exp. Therap. 307(2):682-91 (2003).
International Search Report issued in counterpart PCT Appln. No. PCT/IN2008/000247, (2008).
Written Opinion issued in counterpart PCT Appln. No. PCT/IN2008/000247, (2009).
International Preliminary Report on Patentability issued in counterpart PCT Appln. No. PCT/IN2008/000247, (2009).
Daulatabad Anand Vijaykumar
Dwarampudi Adi Reddy
Jasti Venkateswarlu
Kambhampati Rama Sastri
Kandikere Nagaraj Vishwottam
Chu Yong
IP Horgan Ltd.
Suven Life Sciences Limited
LandOfFree
Aminoalkoxy aryl sulfonamide compounds and their use as 5-HT... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Aminoalkoxy aryl sulfonamide compounds and their use as 5-HT..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aminoalkoxy aryl sulfonamide compounds and their use as 5-HT... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2795046